Acrivon Therapeutics, Inc. Common Stock (ACRV) EV/Sales: History & Chart

Acrivon Therapeutics, Inc. Common Stock(ACRV)

Biotechnology · Watertown, MA

$1.96-0.02 (-1.01%)

Delayed quote: Oct 6, 2026, 10:19 AM EDT

About Acrivon Therapeutics, Inc. Common Stock

Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.

Watertown, MA

75 employees

www.acrivon.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Peter Blume-Jensen

View full financials

NAME	MARKET CAP	EV/SALES RATIO	TTM	3Y	5Y
Acrivon Therapeutics, Inc. Common Stock (ACRV)	$83.89M	N/A	N/A	N/A	N/A
MediciNova, Inc. (MNOV)vs ›	$83.18M	62.89x	119.91x	82.00x	251.31x
Cognition Therapeutics, Inc. (CGTX)vs ›	$84.20M	N/A	N/A	N/A	N/A
Humacyte, Inc. (HUMA)vs ›	$84.03M	33.15x	52.52x	427.47x	706.12x
Conexeu Sciences Inc. (CNXU)vs ›	$84.98M	N/A	N/A	N/A	N/A
Atara Biotherapeutics, Inc. (ATRA)vs ›	$82.35M	14.37x	5.59x	5.59x	17.86x
Cardiff Oncology, Inc. (CRDF)vs ›	$85.55M	151.20x	202.08x	199.51x	216.66x
Citius Oncology, Inc. (CTOR)vs ›	$81.83M	10.62x	15.91x	15.91x	15.91x
LENSAR Inc (LNSR)vs ›	$81.98M	1.17x	1.93x	1.60x	1.28x
CareCloud, Inc. (CCLD)vs ›	$86.90M	0.99x	1.01x	0.60x	0.55x

NAME

MARKET CAP

EV/SALES RATIO

TTM

Acrivon Therapeutics, Inc. Common Stock (ACRV)

$83.89M

N/A

MediciNova, Inc. (MNOV)vs ›

$83.18M

62.89x

119.91x

82.00x